Contributions
Abstract: P1098
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Neurophysiology
Introduction: EPs have good predictive value on disability progression but no data are available about predictive value of EPs on NEDA evolution (No Evidence of Disease Activity) which is the goal for MS treatments.
Methods: 96 MS patients underwent multimodal EP (VEP-BAEP-SEP-MEP) at first-line treatment initiation. All patients received a 2.5±0.8 years clinical and neuro-radiological follow-up; 59 of them received a 7±1,4 years follow-up. Each EPs was assessed with an abnormality score (0 to 3); maximum possible multimodal EP score (GEPs) was 36. Patients were defined NEDA if no MRI or clinical activity and no confirmed disability progression occurred during the follow-up.
Results: A total of 35 patients (36.5%) reached NEDA criteria at follow-up. Mean EP score was 4.09 in NEDA patients (n=35) and 7.44 in patients with active disease (n=61, 63.5%), which is significantly higher (Mann-Whitney; p=0.026). Considering single modalities only VEP reached a statistically different percentage of abnormalities (Chi-square; p=0.004) between the two groups. A logistic regression was performed to ascertain the effects of GEPs, MRI lesion load, EDSS and disease duration on the likelihood that participants have NEDA evolution. The model correctly classified 77.1% of cases (p< 0,0001) with significant contribution of GEPs and EDSS. Similar results were obtained to predict first treatment failure (81.3%, p=0.01). Using the same controlling variables GEPs correlated with EDSS at follow-up (partial correlation coefficient=0.37; p< 0.0001).
The small number of NEDA patients (4/59) at the 7 years follow-up limited regression analyses which weren"t statistically significant. However, GEPs correlated with EDSS at 7 years (partial correlation coefficient =0.41; p=0.002).
Discussion: Multimodal evoked potentials give significant information on disease progression at the early stages of the disease and EPs score should be included in treatment decision making process.
Disclosure: L. Moiola received honoraria for speaking at meetings or for attending to advisory board from Sanofi-Genzyme, Biogen-Idec, Novartis and TEVA.
M. Pisa, M. Bianco, S. Guerrieri, G. Di Maggio, M. Romeo: has nothing to disclosure.
V. Martinelli received honoraria for consulting and speaking activities from Biogen, Merck-Serono, Bayer, TEVA, Novartis and Genzyme.
G. Comi received honoraria for consulting services and for speaking activities from Novartis, Teva, Sanofi, Genzyme, Merck, Biogen, Excemed, Roche, Almirall, Chugai, Receptos, Forward Pharma
L. Leocani has received personal compensation from: Biogen (Advisory Board); Almirall, Novartis, Biogen (travel support) Merck Serono (research support).
Abstract: P1098
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Neurophysiology
Introduction: EPs have good predictive value on disability progression but no data are available about predictive value of EPs on NEDA evolution (No Evidence of Disease Activity) which is the goal for MS treatments.
Methods: 96 MS patients underwent multimodal EP (VEP-BAEP-SEP-MEP) at first-line treatment initiation. All patients received a 2.5±0.8 years clinical and neuro-radiological follow-up; 59 of them received a 7±1,4 years follow-up. Each EPs was assessed with an abnormality score (0 to 3); maximum possible multimodal EP score (GEPs) was 36. Patients were defined NEDA if no MRI or clinical activity and no confirmed disability progression occurred during the follow-up.
Results: A total of 35 patients (36.5%) reached NEDA criteria at follow-up. Mean EP score was 4.09 in NEDA patients (n=35) and 7.44 in patients with active disease (n=61, 63.5%), which is significantly higher (Mann-Whitney; p=0.026). Considering single modalities only VEP reached a statistically different percentage of abnormalities (Chi-square; p=0.004) between the two groups. A logistic regression was performed to ascertain the effects of GEPs, MRI lesion load, EDSS and disease duration on the likelihood that participants have NEDA evolution. The model correctly classified 77.1% of cases (p< 0,0001) with significant contribution of GEPs and EDSS. Similar results were obtained to predict first treatment failure (81.3%, p=0.01). Using the same controlling variables GEPs correlated with EDSS at follow-up (partial correlation coefficient=0.37; p< 0.0001).
The small number of NEDA patients (4/59) at the 7 years follow-up limited regression analyses which weren"t statistically significant. However, GEPs correlated with EDSS at 7 years (partial correlation coefficient =0.41; p=0.002).
Discussion: Multimodal evoked potentials give significant information on disease progression at the early stages of the disease and EPs score should be included in treatment decision making process.
Disclosure: L. Moiola received honoraria for speaking at meetings or for attending to advisory board from Sanofi-Genzyme, Biogen-Idec, Novartis and TEVA.
M. Pisa, M. Bianco, S. Guerrieri, G. Di Maggio, M. Romeo: has nothing to disclosure.
V. Martinelli received honoraria for consulting and speaking activities from Biogen, Merck-Serono, Bayer, TEVA, Novartis and Genzyme.
G. Comi received honoraria for consulting services and for speaking activities from Novartis, Teva, Sanofi, Genzyme, Merck, Biogen, Excemed, Roche, Almirall, Chugai, Receptos, Forward Pharma
L. Leocani has received personal compensation from: Biogen (Advisory Board); Almirall, Novartis, Biogen (travel support) Merck Serono (research support).